Interleukin-2 in Metastatic Renal Cell Carcinoma

摘要: Interleukin-2 (IL-2) was first described as a T-cell growth factor (TCGF) in 1976 by Morgan et al. when it noted that conditioned medium could support (1). IL-2 later demonstrated to have no direct antitumor activity, but mediate activity indirectly through the host immune response (2, 3). The primary source of is from an antigen-stimulated TH1-type CD4+ T cell and, lesser extent, activated CD8+ cells (4). At least two external signals are required for activation, one receptor complex (TCR/CD3+), and second accessory expressing B7, ligand CD28+ receptor. It encoded on chromosome 4q26–28 (5) cloned 1983 (6). 15 kD protein consisting paired α helices bound interchain di-sulfide bond between cysteine residues at positions 58 105. interacts with Rβγ heterodimer receptor, structure which similar IL-4 GM-CSF (7).